Interviews

Mayuko Sakae, MD, discusses findings from research presented at the 2024 Multinational Association of Supportive Care in Cancer Annual Meeting on refractory pain in patients who have undergone a bone marrow transplant.

In an interview, Benjamin H. Lowentritt, MD, FACS, compared PSA response rates between apalutamide and enzalutamide in patients with metastatic castration-sensitive prostate cancer.

Taiga Nishihori, MD, discusses the findings from a study evaluating ciltacabtagene autoleucel given in the outpatient setting to patients with relapsed/refractory multiple myeloma.

In an interview with Targeted Oncology, John Mascarenhas, MD, discussed the lead up to the SENTRY trial and its potential impact on the treatment of myelofibrosis.

The FDA has granted 510(k) clearance to the SeCore™ CDx HLA A sequencing system as companion diagnostic for afamitresgene autoleucel in synovial sarcoma, paving the way for a first-of-its-kind solid tumor therapy.

In an interview, Timothy F. Cloughesy, MD, discussed the recent approval of vorasidenib in IDH-mutant gliomas and data from the phase 3 INDIGO trial.

In an interview with Targeted Oncology, Richard Lee, MD, discussed what integrative oncology encompasses and its significance in modern cancer care.

Timothy F. Cloughesy, MD, discusses the impact and significance of the FDA’s approval of vorasidenib, a first-in-class option for the treatment of patients with IDH-mutant gliomas.

Suresh S. Ramalingam, MD, discussed the practice-changing findings and implications of the phase 3 LAURA study investigating osimertinib for the treatment of patients with EGFR-mutated non–small cell lung cancer.

Douglas Tremblay, MD, discusses the different cytoreduction approaches available to patients with myeloproliferative neoplasms and their safety profiles.

Yannis K. Valtis, MD, provides background on a single-institution, retrospective cohort study which assessed laboratory and clinical tumor lysis syndrome in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Paula Rodríguez Otero, MD, PhD, discussed the findings from the minimal residual disease analysis of the PERSEUS study.

Ayal Aizer, MD, MHS, discussed the changing treatment paradigms of treatment of brain metastases in patients with small cell lung cancer.

Harry Erba, MD, PhD, provided his insights into the groundbreaking myeloMATCH trial and its influence on the treatment of acute myeloid leukemia and myelodysplastic syndromes.

Edwin Choy, MD, PhD, discusses the mechanism of action of afamitresgene autoleucel and the recent accelerated approval from the FDA for patients with advanced synovial sarcoma.

Mayuko Sakae, MD, discussed research on pain management for patients undergoing bone marrow transplants, highlighting the potential buprenorphine shows in offering a valuable alternative to traditional opioids.

Nicolas Girard, MD, PhD, discussed findings from the PALOMA-2 study investigating subcutaneous vs intravenous amivantamab plus lazertinib for previously untreated, EGFR-mutant non–small cell lung cancer.

Pierfranco Conte, MD, discusses findings and implications of the A-BRAVE study.

Harry Erba, MD, PhD, discusses myeloMATCH, a precision medicine umbrella trial for patients with acute myeloid leukemia or myelodysplastic syndrome.

Andrew Brohl, MD, discussed findings from a study investigating a novel vaccine treatment for squamous cell and Merkel cell carcinomas.

A study suggests a PIK3CA mutation and blood tests before and after treatment may predict response to alisertib in HR+/HER2–metastatic breast cancer.

Mridula George, MD, discussed a study investigating ctDNA monitoring during neoadjuvant therapy of breast cancer.

Neel Bhatt, MBBS, MPH, discusses a study exploring long-term quality of life outcomes of patients who underwent stem cell transplantation for aplastic anemia.

Daniel Rubin, PharmD, discusses key takeaways from a study exploring the use. of a clinical decision tool for biomarker documentation.

Taiga Nishihori, MD, discusses a study in which investigators evaluated patients with relapsed/refractory multiple myeloma who were hospitalized and treated with commercial ciltacabtagene autoleucel at Moffitt Cancer Center between May 2022 and May 2023.

Juneko Grilley-Olson, MD, discussed findings from a phase 2 study investigating the addition of immunotherapy to chemotherapy for the treatment of advanced angiosarcoma.

Vincent Law, research associate at Moffitt Cancer Center, discusses the key takeaways and implications of this research.

Alexandra Gomez Arteaga, MD, discusses the rationale behind a retrospective study comparing Orca-T with posttransplant cyclophosphamide-based hematopoietic cell transplantation.